ARCHIVES

Phase II Study Of Pfizer Drug Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

Model Projects 54,900 New Lung Cancer Cases In 5 Years with Nationwide LDCT Screening

May 30, 2014

NCI Names Brawly Director of Office of Special Populations

June 21, 1996

Cancer Policy: President’s Cancer Panel Issues Statement On National Cancer Program

September 17, 1999

ACCC Seeks Expanded Backing For CHOP, Other Community Cancer Programs

November 7, 1980

Afinitor Extends PFS In Women With EGFR-2 Positive Disease

June 28, 2013